First day of trading in warrants of series 2023/2024 TO2

In December 2023, Cell Impact AB (publ) (Nasdaq First North Growth Market: CI) ("Cell Impact" or the "Company") carried out a rights issue of Units (the “Rights Issue”). The first day of trading in warrants of series 2023/2024 TO2 (the "Warrants") issued as part of the Rights Issue on Nasdaq First North Growth Market is tomorrow, 19 December 2023. The last day of trading in the Warrants is 25 September 2024. The Warrants will be traded under the short name (ticker) CI TO2.

Through the Rights Issue, 128,905,776 Warrants have been issued.

Each Warrant entitles the holder to subscribe for one (1) new share in the Company during the period 16 September 2024 up to and including 30 September 2024. The subscription price for subscription of shares by exercise of Warrants corresponds to 70 percent of the volume-weighted average price of the Company’s share on Nasdaq First North Growth Market during the period 2 September 2024 up to and including 13 September 2024. However, the subscription price can at a minimum amount to SEK 0.12 and at a maximum amount to SEK 0.44 per share.

Advisers
In conjunction with the Rights Issue, the Company has engaged Carnegie Investment Bank AB (publ) as Sole Global Coordinator and Joint Bookrunner and Pareto Securities AB as Joint Bookrunner. Advokatfirman Vinge acts as legal adviser to the Company and Baker McKenzie represents Sole Clobal Coordinator and Joint Bookrunners in connection with the Rights Issue.